Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Disitamab vedotin plus pembrolizumab versus platinum-gemcitabine chemotherapy for previously untreated HER2-expressing advanced urothelial carcinoma
NL-OMON60025Phase 3Active, not recruiting
- Sponsor
- Seagen Inc.
- Start
- May 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of disitamab vedotin and pembrolizumab in transitional cell carcinoma (TCC) (2 arms), sponsored by Seagen Inc. Primary endpoints: Progression-free survival by blinded independent central review and Overall survival. Started May 2025; status: active, not recruiting.
02
Drugs
disitamab vedotinpembrolizumab
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on NL-OMON60025.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60025.